Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jasper Therapeutics Inc. (JSPR:NASDAQ), powered by AI.
Jasper Therapeutics Inc. is currently trading at $0.74. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jasper Therapeutics Inc. on Alpha Lenz.
Jasper Therapeutics Inc.'s P/E ratio is -0.2.
“Jasper Therapeutics Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -230.3%.”
Ask for details →Jasper Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for disease treatment, particularly in the field of hematopoietic cell transplantation, autoimmune diseases, and chronic immune disorders. The company's approach relies on targeted technologies aimed at improving the safety and effectiveness of blood and immune system replacement therapies. This is critical in medical procedures like bone marrow transplants where the treatment preconditioning traditionally includes high-dose chemotherapy or radiation, posing significant risks to patients. Jasper Therapeutics strives to provide safer and more effective alternatives, thereby offering a potentially transformative impact on patient outcomes in these sectors. As an entity within the biotechnology industry, its developments have significant implications for healthcare advancements and patient care methodologies. Jasper Therapeutics is strategically positioned within the biotech market, making substantial contributions through its research and development efforts towards better treatment paradigms in its niche areas.
“Jasper Therapeutics Inc. trades at a P/E of -0.2 (undervalued) with modest ROE of -230.3%.”
Ask for details →Jasper Therapeutics Inc. (ticker: JSPR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 64 employees. Market cap is $14M.
The current price is $0.737 with a P/E ratio of -0.19x and P/B of 3.4x.
ROE is -230.31%.